Pacira BioSciences PCRX 深 滬
等待開盤 10-08 09:30:00 美东时间
25.20
+0.440
+1.78%
華盛通- 最 高25.99
- 今 開25.05
- 成交量 79.07万股
- 最 低 24.99
- 昨 收 24.76
- 總市值 10.05亿
- 52周最高 27.66
- 市盈率 靜 161.33
- 換手率 1.98%
- 52周最低 18.80
- 委 比 37.82%
- 總股本 3986.19万
- 歷史最高 121.95
- 量 比 1.49
- 振 幅 4.04%
- 歷史最低 6.51
- 每 手 1
- 風險率 1.69%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Pacira taps Molteni to expand EXPAREL sales across EU and U.K
Pacira BioSciences (PCRX) signed an exclusive agreement with Molteni Farmaceutici to distribute and commercialize EXPAREL in the European Union and U.K. Under the agreement, Pacira will receive an und...
10-05 20:32
Pacira Announces Exclusive Agreement with Molteni Farmaceutici to Commercialize EXPAREL® in the European Union and United Kingdom
Pacira BioSciences partners with Molteni Farmaceutici to expand access to EXPAREL, a non-opioid postsurgical pain management solution, across European markets. Molteni will distribute and commercialize EXPAREL in key European countries, starting with Italy, Germany, Austria, and Poland, with the first sales expected in 2027. This collaboration aligns with Pacira's 5x30 growth strategy and Molteni's expansion goals, aiming to address unmet needs i...
10-05 12:00
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Oppenheimer Initiates Coverage On Pacira BioSciences with Outperform Rating, Announces Price Target of $32
Oppenheimer analyst Les Sulewski initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Outperform rating and announces Price Target of $32.
09-23 18:33
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
Leerink Partners Initiates Coverage On Pacira BioSciences with Market Perform Rating, Announces Price Target of $28
Leerink Partners analyst Daniel Clark initiates coverage on Pacira BioSciences (NASDAQ:PCRX) with a Market Perform rating and announces Price Target of $28.
09-09 23:21
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences granted inducement awards to five new employees under its 2014 Inducement Plan on September 2, 2026, approved by the People & Compensation Committee without shareholder approval. Three employees received stock options for 8,900 shares with a 10-year term and a four-year vesting schedule, exercisable at $26.58 per share. Five employees received restricted stock units for 14,000 shares, vesting annually over four years starting S...
09-09 12:00
Pacira BioSciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Pacira BioSciences granted inducement awards to five new employees under its 2014 Inducement Plan. Two employees received stock options for 8,500 shares, and five received restricted stock units for 14,200 shares. The stock options have a 10-year term, a four-year vesting schedule, and an exercise price of $27.62 per share. Restricted stock units vest annually over four years. Pacira, a leader in non-opioid pain therapies, offers products like EX...
08-07 12:00
美股大行评级 | AMD、Arista Networks、Booking 、加特纳、Pinterest、科力斯、Wayfair等获多家大行上调目标价
今日重点评级关注：HC Wainwright & Co.：维持Precigen"买入"评级，目标价从14美元升至18美元；HC Wainwright & Co.：维持Sophia Genetics"买入"评级，目标价从12美元升至14美元
08-06 11:36
Pacira BioSciences shares are trading higher after the company reported better-than-expected Q2 sales results.
Pacira BioSciences shares are trading higher after the company reported better-than-expected Q2 sales results.
08-06 01:41
